Trials / Withdrawn
WithdrawnNCT07026916
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
A Single-Arm, Multicenter, Open-Label, Phase II Clinical Study to Evaluate the Efficacy, Safety/Tolerability, and Pharmacokinetic Characteristics of GFH375 Monotherapy in Patients With Previously Treated KRAS G12D Mutant Metastatic Pancreatic Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, phase II study to explore the efficacy, safety/tolerability and pharmacokinetics (PK) of GFH375 in in Patients with Previously Treated KRAS G12D Mutant Metastatic Pancreatic Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GFH375 | GFH375 will be administered at the 600mg QD, orally, until disease progression or intolerable toxicity. |
Timeline
- Start date
- 2025-08-01
- Primary completion
- 2027-08-01
- Completion
- 2028-08-01
- First posted
- 2025-06-18
- Last updated
- 2025-11-17
Source: ClinicalTrials.gov record NCT07026916. Inclusion in this directory is not an endorsement.